Ferring Pharmaceuticals has acquired the assets of the USA’s BioSurface Engineering Technologies (BioSET), including two Phase III-ready ‘orthobiologics’ designed to improve bone repair.
The candidates in question, Amplex and Prefix, are based on “a unique biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair”, Ferring says. They will be investigated for fusion in foot/ankle and lumbar spine surgical procedures, respectively.
Orthopaedics has become a key area for Ferring since the 2005 launch of Euflexxa (1% sodium hyaluronate) for knee pain and buying the BioSET portfolio builds on that. Chief operating officer Michel Pettigrew said that “by developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopaedic surgery”.
No financial terms have been disclosed. Switzerland-headquartered Ferring noted that each year some two million procedures involving bone graft materials, including 700,000 fusions, are performed in the USA alone.